Harbin Pharmaceutical Group

ECMOHO Limited Announces Partnership with Vision Care Brand Bausch + Lomb for Sales & Marketing on Pinduoduo

Retrieved on: 
Thursday, October 21, 2021
KOL, Quality of life, Technology, Ecosystem, Sperry, Partnership, Private Securities Litigation Reform Act, Centrum, Bausch & Lomb, Terminology, International Organization (journal), U.S. Securities and Exchange Commission, Pinduoduo, Communication, International, Marketing, Johnson & Johnson, Company, CEO, Lens (anatomy), Harbin Pharmaceutical Group, Abbott, KOC, News, Omron, Health, GLOBE, Securities Exchange Act of 1934, Longevity, ISO, Retail

Through the partnership, ECMOHO provide consumer and Chinese family with high-quality eye care products and family health solution to satisfy the rising demand for eye health.

Key Points: 
  • Through the partnership, ECMOHO provide consumer and Chinese family with high-quality eye care products and family health solution to satisfy the rising demand for eye health.
  • Bausch + Lomb has been a leading vision care company for more than 160 years, and is a global innovation leader who sets the quality standards in this field.
  • Bausch + Lomb has a rich product line, from transparent contact lenses, colored contact lenses, to contact lens care solutions, that fully meet the needs of consumers for achieving clearer vision and improvement in their quality of life.
  • Through this cooperation between ECMOHO and Bausch + Lomb on the Pinduoduo platform, ECMOHO and Bausch + Lomb will be able to empower each other with the unique strength respectively.

A&G Wins Third Award for its Role in Tuesday Morning's Chapter 11 Restructuring and Second for GNC's Successful Turnaround

Retrieved on: 
Monday, September 27, 2021
FTI Consulting, Berkeley Research Group, Goal, Global, BRG, Distress, GNC, Gan, Vinson & Elkins, Bankruptcy, Network, Sale, Multimedia, Association, White, A&G, Latham & Watkins, Grandall Law Firm, Industry, Knowledge, COVID-19, P. J. Solomon, Milbank, Chapter 11, Title 11, United States Code, Harbin Pharmaceutical Group, AlixPartners, Financial adviser, Financial services, Property management

(Those prior awards came from the Global M&A Network and the Turnaround Management Association.)

Key Points: 
  • (Those prior awards came from the Global M&A Network and the Turnaround Management Association.)
  • The M&A Advisor's 15th-Annual Turnaround Awards recognize those deals "that reached the pinnacle of the distressed investing, bankruptcy, and restructuring industry over the past year," according to the New York-based publisher.
  • On GNC's turnaround, A&G teamed with GNC executives and the company's financial advisors to adjust strategy and goals post-bankruptcy filing.
  • The GNC restructuring won in the category of "Cross-Border Restructuring of the Year" ($500MM to $1B).

China Pharmaceutical Distribution Industry Report, 2019-2025 - ResearchAndMarkets.com

Retrieved on: 
Monday, June 10, 2019
Health, Pharmaceutical, Health, Articles, Pharmaceutical industry in China, Pharmaceuticals policy, Pharmacy in China, Science and technology in the People's Republic of China, China National Pharmaceutical Group, Pharmaceutical industry, Sinopharm Group, Harbin Pharmaceutical Group

The "China Pharmaceutical Distribution Industry Report, 2019-2025" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "China Pharmaceutical Distribution Industry Report, 2019-2025" report has been added to ResearchAndMarkets.com's offering.
  • In China, a competitive pattern has taken shape that national drug distributors led by Sinopharm, China Resources Pharmaceutical Group, Shanghai Pharmaceuticals and Jointown Pharmaceutical Group, and regional distribution companies such as Nanjing Pharmaceutical, Guangzhou Pharmaceuticals, Chongqing Pharmaceutical, Huadong Medicine, Sichuan Kelun Pharmaceutical, Zhejiang Int'l Group, Realcan Pharmaceutical, Guangzhou Liuzhou Pharmaceutical and Luyan Phapma, compete with each other.
  • The immense potential of the pharmaceutical distribution industry has attracted the inrush of capital in recent years, and mergers and acquisitions occurred frequently.
  • China Pharmaceutical Distribution Industry Report, 2019-2025 highlights the following:
    China pharmaceutical distribution industry (development environment, status quo, market size, market structure, competitive pattern and development trends)
    China drug retailing market (market size, gross margin, and net margin, quantity, the share of medical insurance designated stores, per customer transaction, and comparison of operating results between major drug retailers)
    20 Chinese pharmaceutical distribution companies (operation, revenue structure, gross margin, development strategy, etc.